Risankizumab for improving quality of life in adults with moderate-to-severe plaque psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, observational follow-up of roughly 700 adults prescribed risankizumab according to local labels and routine practice. Participants will receive risankizumab as their physician directs and will be followed for up to 2.5 years with visits scheduled as part of normal clinical care. Data collection focuses on patient-reported quality of life and routine clinical information without additional experimental interventions. The study excludes patients currently on other biologics or certain small-molecule therapies and those recently in other clinical studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment.
* Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines.
* Decision to treat with risankizumab is made prior to and independently of study participation.

Exclusion Criteria:

* History of a sleep disorder diagnosis which the patient is currently being treated for.
* Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study.
* Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.

Where it's running

• Dermatology Research Institute - Blackfoot Trail /ID# 276722
  Calgary, Alberta, Canada Recruiting
• Rejuvenation Dermatology - Edmonton Downtown /ID# 276688
  Edmonton, Alberta, Canada Recruiting
• Winnipeg Clinic /ID# 276751
  Winnipeg, Manitoba, Canada Recruiting
• Wiseman Dermatology Research /ID# 276847
  Winnipeg, Manitoba, Canada Recruiting
• Cca Medical Research /ID# 276944
  Ajax, Ontario, Canada Recruiting
• Quinte dermatology /ID# 277497
  Belleville, Ontario, Canada Recruiting

+34 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Julieta Gonzalez Blanco
• Email: julieta.gonzalezblanco@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Risankizumab for Refractory Perianal Fistulizing Crohn's Disease

  This study tests whether risankizumab can help people with Crohn’s disease who have draining perianal fistulas not responding to other treatments.

  Recruiting Phase 4 Hyogo Medical University · Nishinomiya and 3 other locations · NCT07872449

• How safe and well ZP9830 works in people with plaque psoriasis over 8 weeks

  This study tests whether ZP9830 is safe and tolerable in adults with plaque psoriasis for 8 weeks, with a comparison to placebo.

  Recruiting Phase 1 Zealand Pharma · Leiden, South Holland · NCT07733089

• Secukinumab retention in adults with plaque psoriasis and MASLD in Spain

  This study tests how long people with plaque psoriasis and MASLD stay on secukinumab in real-world Spain, using EMR data from several hospitals.

  Recruiting at 9 sites Novartis · Badalona, Barcelona and 8 other locations · NCT07683065

• Guselkumab versus risankizumab for moderate-to-severe Crohn's disease

  This comparison tests whether guselkumab or risankizumab works better to reduce intestinal inflammation in people with moderately to severely active Crohn's disease.

  Recruiting at 162 sites Phase 3 Janssen Research & Development, LLC · Dothan, Alabama and 163 other locations · NCT07499232

• How risankizumab moves through the body after IV vs SC dosing in healthy adults

  This study tests how risankizumab behaves in the body after intravenous and subcutaneous doses in healthy adult volunteers.

  Recruiting at 2 sites Phase 1 AbbVie · Anaheim, California and 1 other locations · NCT07466550

• Long-term ORKA-001 treatment for adults with plaque psoriasis

  This open-label extension will try ORKA-001 long-term in adults with moderate-to-severe plaque psoriasis who completed a previous ORKA-001 study.

  Recruiting at 39 sites Phase 2 Oruka Therapeutics, Inc. · Phoenix, Arizona and 38 other locations · NCT07449702

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.